The combination of capecitabine (Xeloda, Roche) and perifosine (KRX-0401, Aeterna Zentaris/Keryx), an orally active PI3K-AKT inhibitor, has showed good clinical outcomes in patients with CRC[83, 84]. Here, AKT1 is linked to colorectal carcinoma.